Skip to main content
Premium Trial:

Request an Annual Quote

Iverson, Johns Hopkins Ink Deal to Commercialize MDx for Heart Disease, Infertility

NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics said today it has received global exclusive rights from Johns Hopkins University School of Medicine to commercialize a molecular diagnostic test.

The licensing agreement grants Iverson rights to a test for assessing cardiovascular risk in men and women and infertility risk in women. According to Iverson, research by Annabelle Rodriguez-Oquendo at the School of Medicine suggests that mutations within the scavenger receptor class B type 1 (SR-B1) gene is associated with heart disease risk and hormonal and fertility problems in women.

"The importance of finding gene variants that affect the metabolism of cholesterol, especially the healthy fraction, and hormones — hence causing disease — is incredibly important for personalized medicine," Leroy Hood, a co-founder of the Institute for Systems Biology and a member of Iverson's board, said in a statement. "This agreement between Iverson and Johns Hopkins is a wonderful example of a diagnostic test that could significantly improve the health of many patients throughout the world."

Financial and other terms were not disclosed.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

Nature News reports that a new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.